



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY: [Signature]

DATE: April 22, 2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

In Re: Patent Application of
Stanley Stewart Davis, *et al.*

: Group Art Unit 1615

MAY 01 2003

Conf. No.: 6578

TECH CENTER 1600/2900

Appln. No. 09/841,228

: Examiner: Sharon Howard

Filed: April 24, 2001

For: NASAL DRUG DELIVERY
COMPOSITION

: Attorney Docket
: No. 10774-57US
: (WESR/P21724US)

REQUEST FOR RECONSIDERATION

This Request for Reconsideration is provided in response to the non-final Office Action (Paper No. 13) mailed January 8, 2003. It is timely filed on April 22, 2003, in view of the one month extension of time enclosed herewith that extends the time for response up to and including 11 May, 2003.

REMARKS

Claims 1-7, 9-11, and 15-17 are pending in the application.

In Paper No. 13, the Examiner has maintained the rejection under 35 U.S.C. § 103(a) of claims 1-7, 9-11, and rejected claims 15-17 as being unpatentable (obvious) over United States Patent No. 6,096,728 of Collins et al. ("Collins") in view of United States Patent No. 5,811,425 of Woods et al. ("Woods"). As basis for the rejection, the Examiner contends that Collins teaches "an emulsion" that comprises a COX-2 inhibitor and that Woods teaches an emulsion comprising castor oil (a hydroxylated vegetable oil) and a COX-2 inhibitor, as well as other non-steroidal anti-inflammatory drugs include flurbiprofen and ibuprofen. The Examiner concedes that Collins does not teach a hydroxylated oil, but supplies the teachings of Wood of castor oil to allegedly remedy the deficiency of Collins.